Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TF 2-targeted cancer therapy

Drug Profile

TF 2-targeted cancer therapy

Alternative Names: Dual modality imaging - Immunomedics; ImmunoTEP; TF2

Latest Information Update: 08 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics; Nantes University Hospital
  • Class Antibody diagnostics; Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Radiopharmaceutical diagnostics
  • Mechanism of Action CEACAM5 protein inhibitors; Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer; Non-small cell lung cancer; Small cell lung cancer; Thyroid cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 08 Sep 2021 No development reported - Phase-II for Colorectal cancer (Diagnosis) in France (IV) (Gilead pipeline, September 2021)
  • 03 Dec 2020 Immunomedics withdraws a phase I trial prior to enrolment for colorectal cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease in USA (NCT01273402)
  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top